+------------------------------------------------------------------------------+
Sanofi CVR Falls 72% After FDA Rejects MS Drug Lemtrada 2013-12-30 13:06:44.627 GMT
By Catherine Larkin Dec. 30 (Bloomberg) -- Sanofi CVR (GCVRZ) falls as much as 72% pre-mkt to 23c. * CVR holders were due to get $1 if Lemtrada won FDA approval before March 31 and as much as $12 more for certain global sales milestones * NOTE: Earlier, Sanofi Multiple Sclerosis Drug Fails to Win FDA Approval; Sanofi Plans to Appeal FDA Decision
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
To contact the reporter on this story: Catherine Larkin in Chicago at +1-312-443-5968 or clarkin4@bloomberg.net
To contact the editor responsible for this story: Joanna Ossinger at +1-212-617-7789 or jossinger@bloomberg.net